Hypertension Drug's Labeling Problems Prompt GSK Recall

Law360, New York (February 24, 2012, 9:25 PM EST) -- GlaxoSmithKline PLC will recall some 394,000 bottles of a blood-pressure medication in the U.S. after drug labeling problems were revealed at a Novartis AG plant in Nebraska that supplies the medication, the drugmaker said Friday.

GSK referred to “inconsistent packaging line-clearance practices” at Novartis’ Lincoln, Neb., facility saying that even though it had not received any complaints about the wrong drugs in its batches of blood pressure drug DynaCirc CR, it would implement the recall as a precautionary measure against such possible tablet mix-ups.

GSK said...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.